Work Here?
Overview
Preparing a concise company summary for Neumora Therapeutics based on provided description.
About Neumora
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2020
People at Neumora
People at Neumora who can refer or advise you
Simplify's Take
What believers are saying
- NMRA-511 showed clinically meaningful CMAI reduction in Phase Ib, with Phase 2 planned for Q1 2027.
- $182.5M cash runway to Q3 2027 enables continued development of NMRA-898 and NMRA-511.
- NMRA-215 weight-loss data expected end-2026 despite toxicology delay, with monotherapy trials starting H1 2026.
What critics are saying
- Navacaprant Phase 3 failure invalidates kappa opioid mechanism, eliminated lead asset, and caused 50-80% stock drop in June 2026.
- NMRA-215 delayed to Q1 2027 due to rat toxicology findings, blocking class-leading weight-loss revenue stream.
- $182.5M cash insufficient for three Phase III trials plus toxicology resolution by 2027, forcing dilutive financing or asset sale.
What makes Neumora unique
- Proprietary Precision Toolbox combines translational, clinical, and computational tools for precision medicine in CNS diseases.
- Targets novel mechanisms like kappa opioid antagonists and V1aR antagonists instead of traditional drug classes.
- Focuses on three key programs: NMRA-511 for Alzheimer's agitation, NMRA-898 for schizophrenia, and NMRA-215 for obesity.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$916.5M
Above
Industry Average
Funded Over
4 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Company Equity
Paid Vacation
Paid Sick Leave
Paid Holidays
Disability Insurance
Parental Leave
Performance Bonus
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -1%Dr. Dam joins Brenig from Neumora Therapeutics, where she was Vice President of Clinical Development, leading strategy and execution across neuropsychiatry and neurodegeneration programs.
There are no jobs for Neumora right now.
Find jobs on Simplify and start your career today
About Neumora
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2020
There are no jobs for Neumora right now.
Find jobs on Simplify and start your career today